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OBJECTIVE—Hyperglycemia-induced inﬂammation is central in
diabetes complications, and monocytes are important in orchestrat-
ing these effects. Toll-like receptors (TLRs) play a key role in innate
immune responses and inﬂammation. However, there is a paucity of
data examining the expression and activity of TLRs in hyperglyce-
mic conditions. Thus, in the present study, we examined TLR2 and
TLR4 mRNA and protein expression and mechanism of their
induction in monocytic cells under high-glucose conditions.
RESEARCH DESIGN AND METHODS—High glucose (15
mmol/l) signiﬁcantly induced TLR2 and TLR4 expression in THP-1
cells in a time- and dose-dependent manner (P0.05). High glucose
increased TLR expression, myeloid differentiation factor 88, inter-
leukin-1 receptor–associated kinase-1, and nuclear factor-B (NF-
B) p65-dependent activation in THP-1 cells. THP-1 cell data were
further conﬁrmed using freshly isolated monocytes from healthy
human volunteers (n  10).
RESULTS—Pharmacological inhibition of protein kinase C
(PKC) activity and NADPH oxidase signiﬁcantly decreased TLR2
and TLR4 mRNA and protein (P  0.05). Knocking down both
TLR2 and TLR4 in the cells resulted in a 76% (P  0.05) decrease
in high-glucose–induced NF-B activity, suggesting an additive
effect. Furthermore, PKC- knockdown decreased TLR2 by 61%
(P  0.05), whereas inhibition of PKC- decreased TLR4 under
high glucose by 63% (P  0.05). Small inhibitory RNA to p47Phox
in THP-1 cells abrogated high-glucose–induced TLR2 and TLR4
expression. Additional studies revealed that PKC-, PKC-, and
p47Phox knockdown signiﬁcantly abrogated high-glucose–in-
duced NF-B activation and inﬂammatory cytokine secretion.
CONCLUSIONS—Collectively, these data suggest that high glu-
cose induces TLR2 and -4 expression via PKC- and PKC-, respec-
tively, by stimulating NADPH oxidase in human monocytes.
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T
he major cause of death in type 1 and type 2
diabetic patients is atherosclerosis (1–3). The
pathogenesis of the accelerated atherosclerosis
is multifactorial. Inﬂammation is pivotal in the
development of atherosclerosis. Recent studies have
shown that diabetes is a proinﬂammatory state (4–6). We
and others have shown that the proinﬂammatory pheno-
type in diabetes is characterized by elevated plasma
C-reactive protein (CRP), cytokines, chemokines, adhe-
sion molecules, monocytic activity, etc. (4–6). Hypergly-
cemia contributes to vascular complications of diabetes.
High glucose has been shown to induce inﬂammatory
cytokines, chemokines, p38 mitogen-activated protein ki-
nase, reactive oxygen species (ROS), protein kinase C
(PKC), and nuclear factor-B (NF-B) activity in both
clinical and experimental systems (7–12). Several lines of
evidence support a role for oxidative stress in the devel-
opment of diabetes complications (13,14). Diabetic pa-
tients have increased O2
 production in monocytes and
neutrophils (8,13,15); however, the mechanism of the
interactions among these mediators remain unclear.
Toll-like receptors (TLRs) recognize conserved patho-
gen-associated molecular patterns and induce innate im-
mune responses that are essential for host defenses (16).
TLRs are activated by both endogenous and exogenous
agonists of microbial and nonmicrobial origin. TLR activa-
tion by their agonists triggers a signaling cascade, leading
to cytokine production and initiation of an adaptive im-
mune response (17). TLR expression is increased in a
plethora of inﬂammatory disorders, including atheroscle-
rosis and diabetes (18–20). Some of the endogenous
ligands for TLR2 and TLR4 include high-mobility group B1,
biglycan, hyaluronic acid fragments, necrotic cells, serum
amyloid A, advanced glycation end products, and extracel-
lular matrix components (18). Among the TLRs, TLR2 and
TLR4 play an important role in atherosclerosis. TLR2 and
TLR4 bind to components of the Gram-positive and -neg-
ative bacteria, respectively (17). They are expressed in
multiple cells and tissues, primarily in monocytes. TLR2
and TLR4 expression is increased in atherosclerotic
plaque macrophages and in animal models of atheroscle-
rosis (21–25). Plaques of TLR4 knockout mice on a high-fat
diet show reduced lesion size, lipid content, and macro-
phage inﬁltration (22). TLR2/LDLR
/ and TLR2/ApoE
/
double knockout mice are protected from the develop-
ment of atherosclerosis (24). In addition, total loss of
myeloid differentiation factor 88 (MyD88), a common
adapter molecule of TLR2 and TLR4 in the cell, results in
reduced plaque size, lipid content, inﬂammation, and
plasma interleukin (IL)-1 and tumor necrosis factor-
(TNF-) (25).
The interactions among inﬂammation, hyperglycemia,
and diabetes have clear implications for the immune
system. Mohammad et al. (26) reported increased TLR2
and TLR4 expression in type 1 diabetic NOD mice, corre-
lating with increased NF-B activation in response to
endotoxin, and increased proinﬂammatory cytokines. Kim
et al. (27) using TLR2
/ , TLR4
/ knockouts, and NOD
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contributes to the instigation of autoimmune diabetes.
Devaraj et al. (20) showed increased TLR2 and TLR4
expression, intracellular signaling, and TLR-mediated in-
ﬂammation in monocytes with signiﬁcant correlation to
A1C levels in type 1 diabetic patients. Also, Song et al. (28)
reported increased TLR4 mRNA expression in differenti-
ating adipose tissue of db/db mice. Creely et al. (29)
showed increased TLR2 expression in the adipose tissue
of type 2 diabetic patients with strong correlates to
endotoxin levels. These observations taken together sug-
gest a potential role for TLR2 and TLR4 in the pathology of
diabetes with limited mechanistic details.
However, data examining the mechanism of increased
TLR2 and TLR4 expression in diabetes are unknown.
Therefore, this study aimed to test the ability of high
glucose, one of the key abnormalities of the diabetic
condition, to induce TLR expression in human monocytes.
RESEARCH DESIGN AND METHODS
Reagents. THP-1 human monocytic cell line was obtained from American
Type Culture Collection (Manassas, VA). All of the reagents, buffers, antibod-
ies, and small interfering RNAs (siRNAs) used in the study and methods are
detailed and available in an online appendix at http://dx.doi.org/10.2337/db08-
0564.
Cell culture. THP-1 cells were subcultured in endotoxin-free RPMI as
described previously in detail (15,30). We monitored the endotoxin levels in
the culture media and reagents (glucose, mannitol, etc.) using Limulus
Amoebocyte Lysate Assay (Cambrex, Milwaukee, MI), and the average
endotoxin level was 100 EU/ml consistently in all of the experiments,
because any endotoxin contamination interferes with accurate TLR2 and
TLR4 quantitation (20,30).
Treatments. Cells were cultured (1  10
6 cells/ml) for 3 days in 5.5 mmol/l
(normal glucose) or for indicated time points with 10–25 mmol/l glucose, and
as an osmotic control, 9.5–14.5 mmol/l mannitol was added along with normal
glucose with daily changes in media. Cell viability, as determined by trypan
blue exclusion, was 	90%. In addition, cells were pretreated for 2 h with
inhibitors followed by 24 h with normal and high glucose (15 mmol/l) (15,30).
Cell supernatants, lysates, and RNA were collected for enzyme-linked immu-
nosorbent assay (ELISA), Western blotting, and RT-PCR, respectively.
Fluorescence-activated cell sorter analysis of TLR2 and TLR4. TLR2 and
TLR4 expressions were determined using ﬂow cytometry as described previ-
ously (20). Brieﬂy, after treatment with high glucose, cells were incubated
with anti-human TLR2 and TLR4 antibodies or isotype-matched IgG controls
and were analyzed with BD FACS Array Bioanalyzer (BD Biosciences, San
Jose, CA). Results are expressed as mean ﬂuorescence intensity units (MFI)/
10
5 cells. The intra- and interassay coefﬁcient of variation (CV) were deter-
mined to be 10%.
RNA extraction and RT-PCR. RNA was isolated from the monocytes using
TRI reagent (Invitrogen, Carlsbad, CA) reagent. RT-PCR was performed using
TLR2, TLR4, and 18s RNA primers (Invivogen, San Diego, CA) following the
manufacturer’s cycling parameters. Band intensities were determined using
Image Quant Software (GE Healthcare Biosciences, Piscataway, NJ) as
described previously (20). For real-time RT-PCR, primer probe sets were
purchased from Superarray Bioscience (Gaithersburg, MD). Data were calcu-
lated using the 2


CT method and are presented as fold induction of
transcripts for the TLR gene normalized to 18s in cells treated with high
glucose (30,31).
ELISA. IL-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), and TNF-
were measured in the supernatants of monocytes by ELISA (R&D Systems,
Minneapolis, MN), as reported previously (30). The intra- and interassay CV
was between 7 and 10% for all of the assays.
Immunoprecipitation and Western blots. Cell lysates (100 g) were
immunoprecipitated with anti-TLR2 antibody or anti-TLR4 antibody (eBio-
science) overnight at 4°C with gentle rocking. Immune complexes were
resolved, transferred, and probed with phospho- and total antibodies as
indicated in Fig. 3. Stripped membranes were further incubated with -actin.
Representative blots from four different experiments are presented.
siRNA transfection assays. Prevalidated siRNAs were obtained from Am-
bion, and transfection assays were performed as described previously (30,32)
following the manufacturer’s instructions, with suitable vehicle and scram-
bled siRNA controls, and subsequently treated with high glucose (15 mmol/l)
for 24 h.
NF-B transcription factor and PKC activity assays. NF-B p65 DNA
binding activity in the high-glucose–treated nuclear extracts of monocytes and
PKC activity in cytosolic fraction were determined using the nonradioactive
TransAM transcription factor assay (Active Motif, Carlsbad, CA) and immu-
noassays (Stressgen, Ann Arbor, MI), respectively, as described in detail
previously (30) following the manufacturer’s instructions. The intra- and
interassay CV for these assays was 7–10%.
Luciferase reporter gene assays for TLR2 and TLR4. Assays were
performed as described previously (33,34). Brieﬂy, 293T cells were cotrans-
fected with TLR4 and MD2 expression plasmids or TLR2 and TLR1 or TLR6
expression plasmids, a luciferase plasmid containing NF-B(2x)-binding site,
and -galactosidase plasmid and corresponding empty vectors as controls
using SuperFect transfection reagent (Qiagen, Valencia, CA), following the
manufacturer’s instructions. Transfected cells were treated with high glucose
FIG. 1. A: Representative RT-PCR gel of TLR2 and TLR4 mRNA expression in THP-1 cells after glucose challenge as described in RESEARCH DESIGN
AND METHODS. Glucose (5.5 mmol/l) was added to mannitol control. Densitometric values are normalized to 18s rRNA and expressed as mean
ratio  SD. *P < 0.05 vs. mannitol or 5.5 mmol/l glucose; n  6 experiments. B: TLR2 and TLR4 protein expression was measured in THP-1 after
glucose challenge by ﬂow cytometry as described in RESEARCH DESIGN AND METHODS. Glucose (5.5 mmol/l) was added to mannitol control. Values are
expressed as MFI/10
5 cells  SD. *P < 0.05 vs. mannitol or 5.5 mmol/l glucose; n  6 experiments.
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enzyme activities were determined using the Promega Luciferase Assay
System and -Galactosidase Enzyme System (Promega, Madison, WI). Lucif-
erase activity was normalized by -galactosidase activity to correct the
transfection efﬁciency.
Statistical analysis. Results of the experimental studies are reported as
means  SD. Differences were analyzed by ANOVA with appropriate post hoc
analyses. A probability value of P  0.05 was considered signiﬁcant. All
statistical analyses were performed using GraphPad Prizm Software (San
Diego, CA).
RESULTS
As depicted in Fig. 1A, both TLR2 and TLR4 mRNA were
signiﬁcantly increased under hyperglycemic conditions.
High glucose signiﬁcantly increased TLR2 and TLR4 protein
compared with 5.5 mmol/l glucose (Fig. 1B). Because RT-
PCR analysis is only semiquantitative, we used real-time
RT-PCR to quantify the time-dependent changes in TLR2 and
TLR4 mRNA levels. At 15 mmol/l glucose concentration, the
TLR2-to-18s mRNA ratio was signiﬁcantly higher at 12 h (Fig.
2A), whereas the TLR4-to-18s mRNA (Fig. 2C) ratio in-
creased at 6 h compared with normal glucose with corre-
sponding increase in TLR2 and TLR4 protein at 24 h (Fig. 2B
and D). Addition of 9.5 mmol/l mannitol to normal glucose
did not result in increased TLR2 and TLR4 levels, suggesting
that the glucose-induced increase in TLR expression was not
an osmotic effect. Because the maximal increase in TLR2 and
TLR4 expression occurred at 24 h of incubation with high
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FIG. 2. A: TLR2 mRNA expression in THP-1 cells after glucose challenge for indicated time points by real-time RT-PCR as described in RESEARCH
DESIGN AND METHODS. Glucose (5.5 mmol/l) was added to mannitol control. Values are expressed as mean ratio  SD. *P < 0.001 vs. mannitol or 5.5
mmol/l glucose (LG) at 6 h; n  4 experiments. B: TLR2 protein expression in THP-1 cells after glucose challenge for indicated time points by ﬂow
cytometry as described in RESEARCH DESIGN AND METHODS. Glucose (5.5 mmol/l) was added to mannitol control. Values are expressed as MFI/10
5
cells  SD. *P < 0.05 vs. mannitol or 5.5 mmol/l glucose (LG); n  4 experiments. C: TLR4 mRNA expression in THP-1 cells after glucose challenge
for indicated time points by real-time RT-PCR as described in RESEARCH DESIGN AND METHODS. Glucose (5.5 mmol/l) was added to mannitol control.
Values are expressed as mean ratio  SD. *P < 0.001 vs. mannitol or 5.5 mmol/l glucose (LG) at 6 h; n  4 experiments. D: TLR4 protein expression
in THP-1 cells after glucose challenge for indicated time points by ﬂow cytometry as described in RESEARCH DESIGN AND METHODS. Glucose (5.5
mmol/l) was added to mannitol control. Values are expressed as MFI/10
5 cells  SD. *P < 0.05 vs. mannitol or 5.5 mmol/l glucose (LG); n  4
experiments.
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duration.
We determined the time required for the high-glucose–
induced TLR expression to return to basal levels. THP-1
cells incubated in high glucose for 24 h were transferred to
normal glucose medium. The time course for TLR expres-
sion showed that TLR2 levels return to normal glucose
levels at 48 h, whereas TLR4 takes 72 h (supplementary
Fig. 1, which is available in the online appendix). In
addition, we examined TLR2 and TLR4 expression in TLR4
and TLR2 siRNA-transfected cells under high glucose,
respectively. The increased TLR2 expression under high
glucose in TLR4 knockdown cells (9.4  0.6 to 21.7  1.5,
P  0.05) and TLR4 expression in TLR2 knockdown cells
under high glucose was unaffected (9.5  1.2 to 37  0.9,
P  0.05).
High glucose induces MyD88-mediated signaling and
NF-B activity in THP-1 cells. We determined the effect
of high glucose on MyD88-dependent signaling pathway
using immunoprecipitation and Western blotting tech-
niques. TLR2 and TLR4 both activate MyD88 and NF-B,
common downstream signaling components for all TLRs
except TLR3. Therefore, activation of NF-B and produc-
tion of proinﬂammatory cytokines induced by high glucose
was used as a functional readout for the activation of TLR2
and TLR4.
High glucose signiﬁcantly induced MyD88 expression
and IL-1 receptor–associated kinase-1 (IRAK-1) phosphor-
ylation in THP-1 cell lysates compared with normal glu-
cose (Fig. 3A) with no change in -actin levels, suggesting
that the change was not due to cell growth. This was
further conﬁrmed by immunoprecipitation with TLR2 and
TLR4 antibodies and blotting for MyD88 and IRAK-1 (Fig.
3B and C). High glucose induced the activation of NF-B
as determined by transcription factor assay (0.29  0.02
ng/mg nuclear protein) compared with normal glucose
(0.11  0.01 ng/mg protein, P  0.05).
High-glucose–induced NF-B activity and inﬂamma-
tory cytokine expression are abrogated in the ab-
sence of TLR2 and TLR4 expression. To further
investigate TLR2- and TLR4-mediated inﬂammation under
high glucose in monocytes, we used loss of function
approach by knocking down TLR2 and TLR4 genes using
speciﬁc siRNAs in THP-1 cells. After transfection with
TLR2, TLR4, and TLR2
TLR4 siRNAs, cells were incu-
bated in 15 mmol/l glucose for 24 h. Lack of TLR2 in THP-1
cells resulted in 48% decrease in NF-B p65-dependent
activity in the nuclear extracts compared with scrambled
controls (Fig. 4; P  0.05). Similarly, a 45% decrease was
observed in the absence of TLR4 under high glucose (Fig.
4). Knocking down both TLR2 and TLR4 in the cells
resulted in 76% decrease in NF-B activity, suggesting an
additive effect (Fig. 4). Next, we measured IL-1, IL-6,
MCP-1, and TNF- release in the supernatants. Inhibition
of TLR2 resulted in signiﬁcant decreases in IL-1 (80%),
IL-6 (42%), MCP-1 (60%), and TNF- (85%), whereas loss of
TLR4 resulted in 55% (IL-1), 51%(IL-6), 65% (MCP-1), and
89% (TNF-) decreases under high glucose compared with
scrambled controls (Fig. 5A–D; P  0.05).
PKC- and PKC- are involved in high-glucose–in-
duced TLR2 and TLR4 expression. We investigated the
high-glucose–induced TLR2 and TLR4 activation-medi-
ated mechanistic events in THP-1 cells using two strat-
FIG. 3. A: Representative Western blot depicting the effect of high glucose on MyD88 and IRAK-1 phosphorylation in THP-1 cells. After culturing
cells with high glucose, cells were lysed, and cell lysates were blotted for MyD88, total and phospho–IRAK-1, and -actin as described in RESEARCH
DESIGN AND METHODS (n  4). B: Representative Western blot showing enhanced expression of MyD88, IRAK-1, and pIRAK-1 in THP-1 cell lysates
immunoprecipitated with TLR2 antibody after high-glucose challenge as detailed in RESEARCH DESIGN AND METHODS. -Actin was used as a loading
control, n  4 experiments. C: Representative Western blot showing enhanced expression of MyD88, IRAK-1, and pIRAK-1 in THP-1 cell lysates
immunoprecipitated with TLR4 antibody after high-glucose challenge as detailed in RESEARCH DESIGN AND METHODS. -Actin was used as a loading
control, n  4 experiments.
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FIG. 4. Inhibition of TLR2 and TLR4 receptors using siRNA ameliorates
high-glucose–induced NF-B p65-dependent DNA binding activity in
the nuclear extracts of THP-1 cells by ELISA as described in RESEARCH
DESIGN AND METHODS. Values are normalized to milligrams nuclear pro-
tein and expressed as means  SD. *P < 0.05 vs. Sc  high glucose
(HG); Sc, scramble control siRNA; TLR2si, TLR2 receptor siRNA;
TLR4si, TLR4 receptor siRNA. n  4 experiments in duplicate. ,
Mannitol; p, LG (5.5 mmol/l); f, HG (15 mmol/l).
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siRNA technology.
First, we examined the role of PKC in TLR2 and TLR4
activation from THP-1 cells under high glucose. PKC
inhibitors calphostin C (10 mol/l; an inhibitor of PKC-,
-,- ,- ε , and -), GF109203X (5 mol/l; an inhibitor of
PKC,- , and -ε ), and chelerythrine (not isoform-selective
PKC inhibitor; competitively interferes with the phosphate
acceptor site and noncompetitively inhibits the ATP-bind-
ing site; 5 mol/l) resulted in a signiﬁcant decrease in
TLR2 and TLR4 expression (Fig. 6A) in THP-1 cells com-
pared with normal glucose.
Second, we determined which isoform of PKC mediates
TLR2 and TLR4 expression from human monocytes under
high glucose, using isotype gene-speciﬁc siRNAs to PKC-,
PKC- (), and PKC-. PKC- siRNA signiﬁcantly de-
creased TLR2 expression (protein and mRNA) in THP-1
cells (60%), whereas inhibition of PKC- decreased TLR4
expression by 63%. PKC- siRNA had no effect on TLR2
and TLR4 expression (Fig. 6C and D).
NADPH oxidase cytosolic subunit p47Phox is in-
volved in high-glucose–induced TLR2 and TLR4 ex-
pression in THP-1 cells. NADPH oxidase is accepted as
the most important mechanism for ROS generation in
phagocytic cells. Previously, we have shown that p47Phox
is an essential component of monocyte NADPH oxidase
production and required for ROS generation under high-
glucose conditions (15,30). Therefore, we examined the role
of NADPH oxidase (p47Phox) in TLR2- and TLR4-modulated
inﬂammation under high glucose using pharmacological in-
hibitors (apocyanin and diphenyleneiodonium) and siRNAs.
Cells were pretreated with the inhibitors followed by expo-
sure to high glucose for 24 h. Both inhibitors signiﬁcantly
decreased TLR2 and TLR4 expression in THP-1 cells under
high glucose (Fig. 6B).
In a second set of experiments, p47Phox siRNA-trans-
fected cells were exposed to high glucose for 24 h. TLR2
and TLR4 surface expression was measured by ﬂow
cytometric analysis. p47Phox knockdown resulted in 45%
inhibition in TLR2 and 50% decrease in TLR4 expression
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FIG. 5. A: IL-1 concentration in supernatants of THP-1 cells after high-glucose treatment in the absence of TLR2 and TLR4 was measured using
ELISA. Values are normalized to milligrams cell protein. *P < 0.05 vs. mannitol; **P < 0.05 vs. Sc  high glucose (HG); Sc, scramble control siRNA;
TLR2si, TLR2 receptor siRNA; TLR4si, TLR4 receptor siRNA. n  4 experiments in duplicate. B: IL-6 concentration in supernatants of THP-1 cells
after high-glucose treatment in the absence of TLR2 and TLR4 was measured using ELISA. Values are normalized to milligrams cell protein. *P <
0.05 vs. mannitol; **P < 0.05 vs. Sc  HG; Sc, scramble control siRNA; TLR2si, TLR2 receptor siRNA; TLR4si, TLR4 receptor siRNA. n  4
experiments in duplicate. C: MCP-1 concentration in supernatants of THP-1 cells after high-glucose treatment in the absence of TLR2 and TLR4
was measured using ELISA. Values are normalized to milligrams cell protein. *P < 0.05 vs. mannitol; **P < 0.05 vs. Sc  HG; Sc, scramble control
siRNA; TLR2si, TLR2 receptor siRNA; TLR4si, TLR4 receptor siRNA. n  4 experiments in duplicate. D: TNF- IL-1 concentration in
supernatants of THP-1 cells after high-glucose treatment in the absence of TLR2 and TLR4 was measured using ELISA. Values are normalized to
milligrams cell protein. *P < 0.05 vs. mannitol; **P < 0.05 vs. Sc  HG; Sc, scramble control siRNA; TLR2si, TLR2 receptor siRNA; TLR4si, TLR4
receptor siRNA. n  4 experiments in duplicate. , Mannitol; p, LG (5.5 mmol/l); f, HG (15 mmol/l).
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bled controls (Fig. 6C and D).
PKC signaling is proximal to p47Phox in mediating
high-glucose–induced TLR2 and TLR4 expression.
Based on the identiﬁcation of p47Phox, PKC-, and PKC-
as mediators of TLR2 and TLR4 expression, respectively,
under high glucose, we sought to determine the proximal
signaling mediator using siRNA knockdown strategy.
1) Because PKC- and PKC- are known to activate
p47Phox, we examined the effect of p47Phox inhibition on
PKC-, PKC-, and PKC- mRNA expression. In p47Phox
siRNA-transfected high-glucose–exposed cells, PKC-
(1.4  0.1 to 1.26  0.3 PKC/18s) and PKC- (1.4  0.3 to
1.3  0.15 PKC/18s) ratios were unchanged as assessed
by real-time RT-PCR, indicating that PKC- and PKC- are
proximal to p47Phox.
2) In PKC-, PKC-, and PKC- siRNA-transfected cells
challenged with high glucose, p47Phox mRNA–to–18s ra-
tios did not change with PKC- inhibition (data not
shown) but signiﬁcantly decreased with PKC- (1.6  0.1
to 0.5  0.03 p47Phox-to-18s ratio) and PKC- (1.4  0.2 to
0.5  0.09 p47Phox-to-18s ratio) inhibition, suggesting that
p47Phox is downstream of PKC.
High glucose also induces other TLRs. To identify
other TLRs and associated signaling mediators induced
under high glucose, we used sensitive, quantitative, and
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FIG. 6. A: Effect of PKC inhibitors (calphostin C, chelerythrine, and GF109203X) on TLR2 and TLR4 protein expression in THP-1 cells. After
culturing cells with inhibitors and high glucose, cells were washed, labeled, and analyzed by ﬂow cytometry as described in RESEARCH DESIGN AND
METHODS. Values are expressed as MFI/10
5 cells  SD. *P < 0.05 vs. high glucose; n  4 experiments. B: Effect of NADPH oxidase inhibitors
(apocyanin and DPI) on TLR2 and TLR4 protein expression in THP-1 cells. After culturing cells with inhibitors and high glucose, cells were
washed, labeled, and analyzed by ﬂow cytometry as described in RESEARCH DESIGN AND METHODS. Values are expressed as MFI/10
5 cells  SD. *P <
0.05 vs. high glucose; n  4 experiments. C: Inhibition of NADPH oxidase subunit p47Phox and PKC isoforms using siRNAs effects
high-glucose–induced TLR2 and TLR4 protein expression of THP-1 cells by ﬂow cytometry as described in RESEARCH DESIGN AND METHODS. Values are
expressed as MFI/10
5 cells  SD. *P < 0.05 vs. scramble control siRNA  LG; **P < 0.05 vs. scramble  high glucose (HG); p47, p47Phox siRNA;
P-, PKC- siRNA, P-, PKC- siRNA; P-, PKC- siRNA; , present; , absent. n  4 experiments in duplicate. D: Inhibition of NADPH oxidase
subunit p47Phox and PKC isoforms using siRNAs effects high-glucose–induced TLR2 and TLR4 mRNA expression of THP-1 cells by real-time
RT-PCR as described in RESEARCH DESIGN AND METHODS. Values are expressed as mean ratio  SD. *P < 0.05 vs. scramble control siRNA  LG; **P <
0.05 vs. scramble  HG; p47, p47Phox siRNA; P-, PKC- siRNA; P-, PKC- siRNA; P-, PKC- siRNA; , present; , absent. n  4 experiments
in duplicate. ,TLR2; f, TLR4.
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Twenty-one genes were expressed at signiﬁcantly higher
levels in high-glucose–treated cells compared with normal
glucose, including TLR2, TLR3, TLR4, TLR6, TLR7, MyD88,
and IRAK-1 (supplementary Table 1, which is available in
the online appendix), further conﬁrming our data.
High glucose induces dimerization of TLR2 with
TLR6 in 293T cells. To further conﬁrm high-glucose–
induced TLR2 and TLR4 expression, we used reporter-
based cotransfection assays (33). High glucose induced
signiﬁcant NF-B transactivation in TLR4-MD2–cotrans-
fected 293T cells (control, 86  3 compared with high
glucose, 288  9 relative luciferase activity [RLA], P 
0.05). Lee et al. (33) previously showed that TLR2 dimer-
izes with TLR1 or TLR6 and results in receptor activation
and downstream signaling upon nonsaturated fatty acid
challenge. To determine whether TLR1 or TLR6 is required
for the activation of TLR2 by high glucose, 293T cells were
cotransfected with murine TLR2 and either TLR1 or TLR6.
High glucose activated NF-B when TLR2 was cotrans-
fected with TLR6 (control, 115  3.5 compared with high
glucose:, 319  6 RLA, P  0.05) and not TLR1. Puriﬁed
lipopolysaccharide, Pam3CysSerLys4 (Pam3CSK4), and
macrophage activating lipopeptide 2Kda were used as
positive controls (data not shown). These results demon-
strate that high glucose induces the TLR4 and TLR2
receptor activity and engagement, resulting in NF-B
activation and further conﬁrming our data.
Additionally, we conﬁrmed the in vitro mechanism of
TLR2 and TLR4 activation under high-glucose conditions
in human monocytes (n  10 healthy volunteers; Fig. 7)
using identical assays.
DISCUSSION
The cellular and molecular mechanisms whereby diabetes
accelerates cardiovascular disease remain to be eluci-
dated. The Diabetes Control and Complications Trial and
Epidemiology of Diabetes Interventions and Complica-
tions Studies clearly showed that reducing glycemia with
insulin treatment decreases cardiovascular events (1–3).
Hyperglycemia induces inﬂammation, affects extracellular
matrix and procoagulant proteins, increases apoptosis in
endothelial cells, decreases proliferation, and inhibits ﬁ-
brinolysis, resulting in endothelial dysfunction. Hypergly-
cemia also induces oxidative stress (4–7).
In this study, we make the novel observation that the
expression and activity of TLR2 and TLR4, key innate
immune system sensors, under high-glucose conditions
are increased, we delineate the corresponding signaling
events, and we demonstrate functional activation in hu-
man monocytes. Our results show that high glucose dose-
and time-dependently induces a marked increase in TLR2
and TLR4 mRNA and protein expression, and these effects
are not osmotic because mannitol had no effect. THP-1
cells are a well-characterized human monocytic cell line,
and data were further conﬁrmed in human monocytes.
Signaling through TLRs is believed to be the critical ﬁrst
step in monocytes activation. Increase in TLR2 and TLR4
expression observed here is consistent with those re-
ported in macrophages of atherosclerotic lesions (35),
human endothelial cells (36) smooth muscle cells of
coronary arteries (37), dendritic cells (38), keratinocytes
(39), preadipocytes (40), adipocytes (41), and pancreatic
islets (27). However, all of these studies were performed
under nondiabetic conditions with minimal information on
the TLR-mediated downstream signaling and mechanism
of activation. In this context, we have provided sequential
data that in human monocytes, high glucose results in
increased TLR2 and TLR4 expression and activity, result-
ing in MyD88-dependent signaling and culminating in
NF-B transactivation, leading to signiﬁcant proinﬂamma-
tory cytokine secretion. Inhibition of TLR2 and TLR4
together in cells was additive, resulting in a further de-
crease in NF-B activity, indicating that activation of both
receptors is critical. This mechanism involves PKC and
NADPH oxidase activation, thus elaborating the steps that
potentiate TLR2 and TLR4 activation-mediated inﬂamma-
tion seen in diabetes.
TLRs activate two types of downstream signaling path-
ways: MyD88-dependent and MyD88-independent pathways
(16). MyD88 is an immediate and common downstream
adaptor molecule recruited by activated TLRs through
their Toll-IL-1 receptor domain domain. MyD88, in turn,
recruits IRAK and induces phosphorylation. IRAK-1 asso-
ciates with TRAF6, leading to the activation of IKK com-
plex and resulting in the activation of NF-B transcription
factor. The activation of MyD88-dependent signaling path-
way leads to the induction of inﬂammatory cytokines. In
this study, we show that TLR2 and TLR4 activation re-
cruits the MyD88-dependent signaling pathway. We dem-
onstrate increased expression of MyD88, phosphorylation
of IRAK-1, and activation of NF-B with concomitant
increase in inﬂammatory cytokine secretion.
However, the fundamental question of how high glucose
activates TLR2 and TLR4 in the monocytes and how this
leads to increased inﬂammation needs to be determined.
Dimerization is a critical event in the functional activation
of TLRs (33). TLR2 activity requires heterodimerization
with TLR1 or TLR6 to confer sensitivity to agonists (33,42).
Dimerization of the cytoplasmic domain of TLR2 with
TLR6 or TLR1 results in cytokine production. Previous
studies in macrophage cell lines showed that TLR2 and
TLR6 functioned cooperatively to detect Gram-positive
bacteria, peptidoglycan, and zymosan (34). Luciferase
reporter assays suggest that high glucose induces TLR2
and TLR6 heterodimerization, via NF-B activation and
cytokine production, in addition to real-time RT-PCR data
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FIG. 7. TLR2 and TLR4 protein expression was measured in freshly
isolated and pooled human monocytes from healthy volunteers (n  3
volunteers/experiment) after glucose challenge by ﬂow cytometry as
described in RESEARCH DESIGN AND METHODS. Values are expressed as
MFI/10
5 cells  SD. *P < 0.05 vs. mannitol or 5.5 mmol/l glucose; n  4
experiments. , TLR2; f, TLR4.
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and TLR6 dimerize to facilitate NF-B and inﬂammatory
gene activation. The dimerization of TLR4 was shown to
be a prerequisite for the ligand-induced receptor activa-
tion, which needs to be determined in addition to under-
standing the role of other TLRs (supplementary Table 1)
under high glucose in future studies. These results suggest
that high glucose induces TLR2 receptor dimerization, and
this, in turn, engages downstream MyD88-dependent sig-
naling pathway.
In an attempt to determine the time taken for the
high-glucose–induced TLR2 and TLR4 expression attun-
ement to basal levels, we transferred high-glucose–ex-
posed cells to normal glucose serum-free media. We
measured TLR2 and TLR4 expression, which suggests that
high-glucose–induced TLR expression persists for 48–72 h
before coming back to normal glucose levels. The physio-
logical consequences of this prolonged expression remain
to be elucidated. In another set of experiments, we mea-
sured TLR2 and TLR4 expression in TLR4- and TLR2-
deﬁcient cells. Our data indicate that both TLR2 and TLR4
are unaffected by the absence of either of them.
The PKC pathway mediates a wide range of cellular
signals and is involved in the activation of NF-B (43).
Published data suggest that all TLR family members acti-
vate nearly identical cytoplasmic signaling pathways ex-
cept TLR3; recently, it was indicated that a TLR2, TLR4,
and PKC axis exists under different conditions. In addition,
diabetes and cells cultured under high glucose show
increases in PKC activity (12,16,30). We previously
showed that increased monocyte superoxide release un-
der high glucose is via activation of PKC- (16,30). To
obtain further insight into the regulation of TLR2 and TLR4
via PKC under high glucose, we used a twin strategy: First,
pharmacological inhibitors of PKC (calphostin C, chel-
erythrine, and GFX2093) inhibited high-glucose–induced
TLR2 and TLR4 expression. Second, inhibition of PKC-
using siRNA reduced TLR2 expression, whereas siRNA of
PKC- resulted in decreased TLR4 expression. Our results
are in line with those observed in neutrophils where both
TLR2 and TLR4 are activated through PKC-/– (44) and
PKC-/–dependent activation in murine macrophages.
Thallas-Bonke et al. (45) report that activation of NADPH
oxidase via PKC- is a key mechanism in diabetic renal
disease. PKC- activation plays a critical role in the
endoplasmic reticulum stress–mediated cell death in car-
diac myocytes and ischemic hearts of rats (46). Bey et al.
(47) showed that PKC- plays a pivotal role in stimulating
monocyte NADPH oxidase activity through its regulation
of phosphorylation and translocation of p47Phox. Further-
more, Ryan et al. (48) recently showed that ROS regulates
TLR4-mediated activation of NF-B and IL-8 expression.
All of these studies strengthen our ﬁndings that TLR2 and
TLR4 are regulated by PKC- and PKC-, and this is
associated with p47Phox-dependent NADPH oxidase ac-
tivity under high glucose.
NF-B signaling occurs via oxidant-sensitive pathways
(49). The NADPH oxidase complex in phagocytic cells and
the generation of oxidants serve a crucial function in host
defense against invading microorganisms (50). In addition,
Shi et al. (51) recently reported that TLR4 is activated by
free fatty acids, acts as a molecular link between inﬂam-
mation and innate immune system, and plays a role in the
regulation of energy balance and insulin resistance in
response to changes in the nutritional environment. Data
from the current study add to increased TLR activity and
increased insulin resistance seen in diabetic milieu. Our
previous studies showed that the monocyte is a key target
of NADPH oxidase activity under high glucose (15,30).
NADPH oxidase–derived oxidants mediate the high-glu-
cose–induced NF-B activation and result in enhanced
IL-6 and IL-1 expression in monocytes (9,15,30). Al-
though high glucose induces oxidative burst in monocytes,
it remains unclear whether the released oxidants contrib-
ute to the high-glucose–induced NF-B activation and thus
are involved in stimulating TLR2-TLR4 expression. It is
possible that increased NF-B binding and ROS generation
may occur early, whereas increased TLR expression may
contribute to NF-B binding later (at 24 h) (12). In this
study, we show inhibitors of NADPH oxidase (apocyanin
and DPI) abrogate high-glucose–induced TLR2 and TLR4
expression in monocytes. We further demonstrate that the
loss of cytosolic component of NADPH oxidase, namely
p47Phox, impairs TLR2 and TLR4 activation under high
glucose that in turn activates NF-B and inﬂammatory
cytokines. Our present results are in accordance with an
earlier report suggesting a TLR4-TLR2 cross-talk mediated
by NADPH oxidase in endothelial cells (36).
It is now established that increased inﬂammation is a
key etiological factor in the development of many chronic
diseases, including cancer, atherosclerosis, and diabetes.
Our results suggest that inﬂammatory effects of high
glucose may be at least in part mediated through the
modulation of inﬂammatory responses resulting from TLR
activation induced by hyperglycemia in diabetes.
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